日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

帕博西尼治疗 CDK4 或 CDK6 扩增肿瘤患者的 II 期研究:NCI-MATCH ECOG-ACRIN 试验 (EAY131) 子方案 Z1C 的结果

O'Hara, Mark H; Jegede, Opeyemi; Dickson, Mark A; DeMichele, Angela M; Piekarz, Richard; Gray, Robert J; Wang, Victoria; McShane, Lisa M; Rubinstein, Lawrence V; Patton, David R; Williams, P Mickey; Hamilton, Stanley R; Onitilo, Adedayo; Tricoli, James V; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T

Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models.

NCI-MPACT 临床前研究:在患者来源的异种移植模型中对基于突变的 NCI-MPACT 临床试验治疗策略进行前瞻性建模

Evrard Yvonne A, Alcoser Sergio Y, Mullendore Michael, Chen Li, Lih Chih-Jian, Kannan Vishnuprabha Rahul, Datta Vivekananda, Dutko Lindsay, Jiwani Shahanawaz, Rubinstein Lawrence V, Zhao Yingdong, Williams P Mickey, Palmisano Alida, Kuhlmann Laura, Simpson Mel, Kummar Shivaani, Das Biswajit, Karlovich Chris, Polley Eric, Li Ming-Chung, Chen Alice P, Hollingshead Melinda G, Doroshow James H

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

曲美替尼治疗NF1、GNAQ或GNA11突变肿瘤患者:NCI-MATCH ECOG-ACRIN试验(EAY131)子方案S1和S2的结果

Wisinski, Kari B; Flamand, Yael; Wilson, Melissa A; Luke, Jason J; Tawbi, Hussein A; Hong, Fangxin; Mitchell, Edith P; Zwiebel, James A; Chen, Helen; Gray, Robert J; Li, Shuli; McShane, Lisa M; Rubinstein, Lawrence V; Patton, David; Williams, P Mickey; Hamilton, Stanley R; Behrens, Robert J; Pennington, Kathryn P; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

基于分子谱的癌症治疗方案分配(NCI-MPACT):一项随机多中心II期试验

Chen, Alice P; Kummar, Shivaani; Moore, Nancy; Rubinstein, Lawrence V; Zhao, Yingdong; Williams, P Mickey; Palmisano, Alida; Sims, David; O'Sullivan Coyne, Geraldine; Rosenberger, Christina L; Simpson, Mel; Raghav, Kanwal P S; Meric-Bernstam, Funda; Leong, Stephen; Waqar, Saiama; Foster, Jared C; Konaté, Mariam M; Das, Biswajit; Karlovich, Chris; Lih, Chih-Jian; Polley, Eric; Simon, Richard; Li, Ming-Chung; Piekarz, Richard; Doroshow, James H

What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?

如何提高肿瘤临床试验中研究活检的质量?

Ferry-Galow, Katherine V; Datta, Vivekananda; Makhlouf, Hala R; Wright, John; Wood, Bradford J; Levy, Elliot; Pisano, Etta D; Tam, Alda L; Lee, Susanna I; Mahmood, Umar; Rubinstein, Lawrence V; Doroshow, James H; Chen, Alice P

Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

分析验证和应用靶向下一代测序突变检测分析方法在 NCI-MPACT 试验治疗分配中的应用

Lih Chih-Jian, Sims David J, Harrington Robin D, Polley Eric C, Zhao Yingdong, Mehaffey Michele G, Forbes Thomas D, Das Biswajit, Walsh William D, Datta Vivekananda, Harper Kneshay N, Bouk Courtney H, Rubinstein Lawrence V, Simon Richard M, Conley Barbara A, Chen Alice P, Kummar Shivaani, Doroshow James H, Williams Paul M

GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials

GeneMed:一个用于协调支持精准肿瘤临床试验的下一代测序研究的信息中心

Zhao, Yingdong; Polley, Eric C; Li, Ming-Chung; Lih, Chih-Jian; Palmisano, Alida; Sims, David J; Rubinstein, Lawrence V; Conley, Barbara A; Chen, Alice P; Williams, P Mickey; Kummar, Shivaani; Doroshow, James H; Simon, Richard M

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

对 III 期临床试验中无进展生存期进行盲法独立中心审查:重要的设计要素还是不必要的开支?

Dodd, Lori E; Korn, Edward L; Freidlin, Boris; Jaffe, C Carl; Rubinstein, Lawrence V; Dancey, Janet; Mooney, Margaret M